Results 131 to 140 of about 1,361,764 (281)

The different face of skin‐rash induced by brentuximab vedotin

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri   +11 more
wiley   +1 more source

Prostaglandin E2 bladder instillation for the treatment of hemorrhagic cystitis after allogeneic bone marrow transplantation

open access: yesHaematologica, 1995
BACKGROUND. Hemorrhagic cystitis (HC) is a major complication of high-dose cyclophosphamide therapy used in the preparative regimen for allogeneic or autologous bone marrow transplantation. Several viruses (adenovirus, cytomegalovirus and polyomavirus BK)
D Laszlo   +10 more
doaj  

SKY92 Identifies High‐Risk Newly Diagnosed Multiple Myeloma With Inferior Progression‐Free Survival and Implicates NUF2 as a Candidate Driver

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera   +24 more
wiley   +1 more source

Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany—A Multi‐Center Analysis

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase‐III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined.
Maria Dampmann   +16 more
wiley   +1 more source

Hematological recovery after autologous bone marrow transplantation for high-grade non Hodgkin's lymphomas: a single center experience

open access: yesHaematologica, 1994
BACKGROUND. Both rhGM-CSF and rhG-CSF can accelerate hematological recovery after high-dose therapy and autologous bone marrow transplantation in patients with high grade non Hodgkin's lymphoma and reduce transplant-related morbidity after ABMT. METHODS.
MC Miggiano   +10 more
doaj  

Comparison of intestinal histopathological changes following teclistamab, BCMA‐directed CAR T, CD19‐directed CAR T and rituximab therapies

open access: yesHistopathology, EarlyView.
This is a retrospective review of intestinal tract biopsies from patients treated with various cellular immunotherapies (BCMA and CD19‐directed CAR T, teclistamab and rituximab therapies). We found distinct but overlapping histologic patterns across treatment groups, with lamina propria plasma cell depletion, crypt apoptotic bodies and active ...
Olivia J Leung   +7 more
wiley   +1 more source

The Imbalance Between Tumor Immunosurveillance and Tumor Immune Escape in Glioblastoma

open access: yesImmunology &Cell Biology, EarlyView.
(Left)The identification and elimination of tumour cells is enabled by the infiltration of functional innate and adaptive immune effectors into the TME, such as natural killer cells (NK cells) and cytotoxic T cells (CD8 T cells). Effective innate and adaptive immune responses facilitate immunological control of malignant outgrowth.
Sarah J. MacDonald   +6 more
wiley   +1 more source

Therapeutic application of EUS-guided intraportal autologous bone marrow transplantation for decompensated liver cirrhosis. [PDF]

open access: yesStem Cell Res Ther
Cai T   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy